The recent events regarding
Edwards Lifesciences (EW) highlight its potential as one of the best bio-tech stocks to buy now, with key presentations at BofA Securities 2025 Health Care Conference and positive SWOT analysis strengthening this claim. Unfortunately, a
securities class-action has been filed against the company, a development that might impact its stock price negatively. Concurrently, it unveiled a key date for Q1 2025 financial report, with reports indicating solid growth in both Q4 and Q1 profits. Investors are incentivized to purchase shares at $60, and significant amendments have been made to the employee stock purchase plans.
Piper Sandler upgraded EW, and despite mixed Q1 results, a raised price target was successfully asserted. In terms of innovation, the company secured CE mark for its groundbreaking Mitral Valve System, suggesting progressive research work within the company that might affect future revenues. The company’s stock has seen a series of fluctuations with reports of substantial losses, and its CFO selling significant quantities of stock.
Jim Cramer, an influential market analyst, has given a 'hold' recommendation on the stock while switching preference to Boston Scientific. However, the release of their Q4 earnings, and subsequent currency boost has lead them to raise the sales forecast for 2025.
Edwards Lifesciences Corp EW News Analytics from Thu, 25 Jul 2024 07:00:00 GMT to Sat, 10 May 2025 04:05:45 GMT -
Rating -2
- Innovation 6
- Information -1
- Rumor -8
